BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33470702)

  • 21. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
    Tabrizian P; Holzner ML; Mehta N; Halazun K; Agopian VG; Yao F; Busuttil RW; Roberts J; Emond JC; Samstein B; Brown RS; Najjar M; Chapman WC; Doyle MM; Florman SS; Schwartz ME; Llovet JM
    JAMA Surg; 2022 Sep; 157(9):779-788. PubMed ID: 35857294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transarterial chemoembolization for intrahepatic multiple recurrent HCC after liver resection or transplantation.
    Cheng YC; Chen TW; Fan HL; Yu CY; Chang HC; Hsieh CB
    Ann Transplant; 2014 Jun; 19():309-16. PubMed ID: 24975583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Guerrini GP; Pinelli D; Marini E; Corno V; Guizzetti M; Zambelli M; Aluffi A; Lincini L; Fagiuoli S; Lucianetti A; Colledan M
    Prog Transplant; 2018 Mar; 28(1):63-69. PubMed ID: 29251164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival.
    Kim HD; Lim YS; Han S; An J; Kim GA; Kim SY; Lee SJ; Won HJ; Byun JH
    Gastroenterology; 2015 Jun; 148(7):1371-82. PubMed ID: 25733098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?
    Fernandez-Sevilla E; Allard MA; Selten J; Golse N; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Adam R
    Liver Transpl; 2017 Apr; 23(4):440-447. PubMed ID: 28187493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma.
    Tsuchiya K; Asahina Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Kurosaki M; Enomoto N; Izumi N
    Liver Transpl; 2014 Mar; 20(3):291-7. PubMed ID: 24734314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma.
    Li JH; Chen T; Xing H; Li RD; Shen CH; Zhang QB; Tao YF; Wang ZX
    Hepatobiliary Pancreat Dis Int; 2023 Jun; 22(3):245-252. PubMed ID: 35534342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk Factors for Hepatocellular Carcinoma Recurrence and Survival after Liver Transplantation in Patients with HCV-Related Cirrhosis.
    Vidal RIO; Vidal EIO; Pereira BB; Assane CC; Ribeiro A; do Nascimento EM; Romeiro FG; Ribeiro Filho J
    Biomed Res Int; 2020; 2020():1487593. PubMed ID: 33134370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Machine learning-based survival rate prediction of Korean hepatocellular carcinoma patients using multi-center data.
    Noh B; Park YM; Kwon Y; Choi CI; Choi BK; Seo KI; Park YH; Yang K; Lee S; Ha T; Hyon Y; Yoon M
    BMC Gastroenterol; 2022 Feb; 22(1):85. PubMed ID: 35220946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma.
    Cha H; Yoon HI; Lee IJ; Koom WS; Han KH; Seong J
    J Radiat Res; 2013 Nov; 54(6):1069-77. PubMed ID: 23633620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection.
    Choi WM; Lee JH; Ahn H; Cho H; Cho YY; Lee M; Yoo JJ; Cho Y; Lee DH; Lee YB; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS; Kim CY; Lee HS
    Liver Int; 2015 Aug; 35(8):1992-2000. PubMed ID: 25556714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percutaneous radiofrequency ablation for early hepatocellular carcinoma: risk factors for survival.
    Kikuchi L; Menezes M; Chagas AL; Tani CM; Alencar RS; Diniz MA; Alves VA; D'Albuquerque LA; Carrilho FJ
    World J Gastroenterol; 2014 Feb; 20(6):1585-93. PubMed ID: 24587635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
    Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.
    Takada Y; Kaido T; Shirabe K; Nagano H; Egawa H; Sugawara Y; Taketomi A; Takahara T; Wakabayashi G; Nakanishi C; Kawagishi N; Kenjo A; Gotoh M; Toyoki Y; Hakamada K; Ohtsuka M; Akamatsu N; Kokudo N; Takeda K; Endo I; Takamura H; Okajima H; Wada H; Kubo S; Kuramitsu K; Ku Y; Ishiyama K; Ohdan H; Ito E; Maehara Y; Honda M; Inomata Y; Furukawa H; Uemoto S; Yamaue H; Miyazaki M; Takada T;
    J Hepatobiliary Pancreat Sci; 2017 Jan; 24(1):49-57. PubMed ID: 27806426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic response to preoperative transarterial chemoembolization for resectable hepatocellular carcinoma may not predict recurrence after liver resection.
    Paik KY; Kim EK
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):158-64. PubMed ID: 27020632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
    Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
    Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
    [No Abstract]   [Full Text] [Related]  

  • 40. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.
    Jiang JH; Guo Z; Lu HF; Wang XB; Yang HJ; Yang FQ; Bao SY; Zhong JH; Li LQ; Yang RR; Xiang BD
    World J Gastroenterol; 2015 Apr; 21(15):4627-34. PubMed ID: 25914472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.